Positive Outlook For Lilly’s Cialis In China
This article was originally published in PharmAsia News
Lilly's second quarter results for 2008 show that Cialis (tadalafil) sales increased 24 percent to $362 million globally. Revenue hit $1.2 billion in 2007, closing the gap between Pfizer's Viagra sales of $1.8 billion. However, according to Lilly China officials, the drug has only broken even after six years in the country, and just starting to turn a profit now. Though Cialis sales in China only account for less than 1 percent of Lilly's worldwide revenue, the country's almost 30 percent growth makes it greatly attractive when compared with the single-digital growth for most markets. (Click here for more - Chinese Language)
You may also be interested in...
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.